Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug duo aims to halt rare Cancer's spread

NCT ID NCT03950609

Summary

This study is testing whether two oral medications, lenvatinib and everolimus, can help control advanced carcinoid tumors that have spread and cannot be surgically removed. The goal is to see if this drug combination can shrink tumors or stop them from growing in 36 participants. Patients take both pills daily in repeating 28-day cycles, and researchers will monitor tumor response and side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.